The most common projected cancers in adults were lung cancer, colon cancer, leukemia, bladder cancer, and stomach cancer.

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

DB-1305/BNT325 was generally well tolerated and exhibited “very encouraging and durable antitumor activity in ovarian cancer patients,” said Maria Rubinstein, MD.

With a 95% retention rate for nurse residents completing the program and a 100% 2-year post-hire retention rate, these initiatives ensure a stable and well-trained workforce.

A team of researchers explain how navigation programs work, who benefits, and how to create a successful navigation program.

Researchers sought to determine whether a pharmacist-led clinic for administering venetoclax would be effective for patients with CLL.

Prior screening mammography linked to earlier stage at breast cancer diagnosis, lower breast cancer mortality.